Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

With fewer than 200 trained dermatologists serving Malaysia's 33 million people[1]-just one specialist for every 165,000 ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

In rare public comments, WA's Public Trustee tells a parliamentary committee the government should consider subsidising the ...

Prothena Corporation plc (NASDAQ:PRTA) is an Ireland-based late-stage clinical biotechnology company that identifies and ...

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over ...

Featuring works from Chelsea Odufu, Laurena Finéus, Jarrett Key, and more, the show challenges how we encounter personal ...

Whyte, 18, a popular Tiktok creator, had 100,00 followers and his account was flooded with over 4,000 comments in the days after his death, including many wishing him a heavenly 19th birthday on ...

Other appointments to BIO's board for the 2025 through 2026 term include: Arcutis Bio's Frank Watanabe, named vice-chair; ...

In late May, Saanich student Nathan Hellner-Mestelman received the TD Scholarship for Community Leadership – an award coveted ...

At the Heart in Diabetes CME Conference, speakers highlighted four recent reports published in the Journal of the American ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...